L S Marks

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies
    Leonard S Marks
    University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, CA, USA
    J Urol 189:S122-8. 2013
  2. ncbi request reprint The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations
    Leonard S Marks
    Department of Urology, School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    J Urol 176:868-74. 2006
  3. ncbi request reprint Prostatic tissue testosterone and dihydrotestosterone in African-American and white men
    Leonard S Marks
    Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
    Urology 68:337-41. 2006
  4. ncbi request reprint Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease
    Leonard S Marks
    Department of Urology, Geffen School of Medicine at UCLA, Urological Sciences Research Foundation, 3831 Hughes Avenue, Culver City, CA 90232, USA
    Curr Urol Rep 7:293-303. 2006
  5. ncbi request reprint Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant
    Leonard S Marks
    Urological Sciences Research Foundation, Culver City, California 90232, USA
    Urology 62:36-42. 2003
  6. ncbi request reprint Prevention of benign prostatic hyperplasia disease
    Leonard S Marks
    Urological Sciences Research Foundation and Department of Urology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90232, USA
    J Urol 176:1299-306. 2006
  7. ncbi request reprint Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial
    Leonard S Marks
    Department of Urology, Geffen School of Medicine, University of California, Los Angeles, USA
    JAMA 296:2351-61. 2006
  8. ncbi request reprint PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
    Leonard S Marks
    Urological Sciences Research Foundation, Los Angeles, California 90232, USA
    Urology 69:532-5. 2007
  9. ncbi request reprint The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response
    Leonard S Marks
    Department of Urology, University of California, Los Angeles School of Medicine and Urological Sciences Research Foundation, Los Angeles, California 90232, USA
    J Urol 177:1408-13. 2007
  10. doi request reprint Prostate tissue androgens: history and current clinical relevance
    Leonard S Marks
    Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
    Urology 72:247-54. 2008

Detail Information

Publications29

  1. doi request reprint Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies
    Leonard S Marks
    University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, CA, USA
    J Urol 189:S122-8. 2013
    ..We evaluated the efficacy and safety of silodosin for treatment of benign prostatic hyperplasia symptoms in 2 randomized, placebo controlled, phase 3 studies...
  2. ncbi request reprint The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations
    Leonard S Marks
    Department of Urology, School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    J Urol 176:868-74. 2006
    ....
  3. ncbi request reprint Prostatic tissue testosterone and dihydrotestosterone in African-American and white men
    Leonard S Marks
    Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
    Urology 68:337-41. 2006
    ..To compare tissue androgen levels in the prostate gland of African-American and white men, looking for a possible explanation of the increased incidence of cancer in the former...
  4. ncbi request reprint Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease
    Leonard S Marks
    Department of Urology, Geffen School of Medicine at UCLA, Urological Sciences Research Foundation, 3831 Hughes Avenue, Culver City, CA 90232, USA
    Curr Urol Rep 7:293-303. 2006
    ..Thus, we now can identify men with an enlarged prostate at risk for BPH disease who may be candidates for preventive therapy with 5ARIs, regardless of urinary symptoms or bother...
  5. ncbi request reprint Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant
    Leonard S Marks
    Urological Sciences Research Foundation, Culver City, California 90232, USA
    Urology 62:36-42. 2003
    ..Thus, a long-term strategy-permitting increased patient freedom and decreased dependence on a fixed injection schedule-has for the first time become possible with the Viadur implant in men requiring hormone therapy for prostate cancer...
  6. ncbi request reprint Prevention of benign prostatic hyperplasia disease
    Leonard S Marks
    Urological Sciences Research Foundation and Department of Urology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90232, USA
    J Urol 176:1299-306. 2006
    ..We reviewed the evidence that benign prostatic hyperplasia is a progressive condition and men at risk for benign prostatic hyperplasia disease can be identified, treated and protected to a meaningful extent regardless of symptom status...
  7. ncbi request reprint Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial
    Leonard S Marks
    Department of Urology, Geffen School of Medicine, University of California, Los Angeles, USA
    JAMA 296:2351-61. 2006
    ..Prostate safety is a primary concern when aging men receive testosterone replacement therapy (TRT), but little information is available regarding the effects of TRT on prostate tissue in men...
  8. ncbi request reprint PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
    Leonard S Marks
    Urological Sciences Research Foundation, Los Angeles, California 90232, USA
    Urology 69:532-5. 2007
    ..We evaluated the potential utility of the investigational prostate cancer gene 3 (PCA3) urine assay to predict the repeat biopsy outcome...
  9. ncbi request reprint The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response
    Leonard S Marks
    Department of Urology, University of California, Los Angeles School of Medicine and Urological Sciences Research Foundation, Los Angeles, California 90232, USA
    J Urol 177:1408-13. 2007
    ..We determined the effects of dutasteride on transition and peripheral zone volume, and the clinical value of the transition zone index in men with benign prostatic hyperplasia...
  10. doi request reprint Prostate tissue androgens: history and current clinical relevance
    Leonard S Marks
    Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
    Urology 72:247-54. 2008
    ..Determination of prostate tissue androgens may soon transition from research tool to clinical test...
  11. doi request reprint Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies
    Leonard S Marks
    University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, California, USA
    J Urol 181:2634-40. 2009
    ..We evaluated the efficacy and safety of silodosin for treatment of benign prostatic hyperplasia symptoms in 2 randomized, placebo controlled, phase 3 studies...
  12. ncbi request reprint The role of prostate needle biopsy in evaluation of chemopreventive agents
    L S Marks
    Urological Sciences Research Foundation and Department of Urology, UCLA School of Medicine, Los Angeles, California, USA
    Urology 57:191-3. 2001
    ..The serial biopsy approach may be especially valuable in "watchful waiting" cohorts...
  13. ncbi request reprint Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens
    L S Marks
    Urological Sciences Research Foundation, Culver City, California, USA
    Urology 57:999-1005. 2001
    ..The SPHB-induced suppression of prostatic DHT levels, modest but significant in a randomized trial, lends an element of support to the hypothesis that inhibition of the enzyme 5-alpha reductase is a mechanism of action of this substance...
  14. ncbi request reprint Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents
    A W Partin
    James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Department of Urology, Baltimore, Maryland, USA
    Urology 57:132-6. 2001
    ..This update will focus on a critical evaluation of prostate-specific antigen (PSA), percentage of free PSA, and human glandular kallikrein-2 (hK2) and how they may be used or misused for chemoprevention studies...
  15. ncbi request reprint Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia
    Michael Marberger
    Department of Urology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Clin Endocrinol Metab 91:1323-8. 2006
    ..Although benign prostatic hyperplasia (BPH) is an androgen-dependent disorder, little is known regarding the influence of serum testosterone levels on sexual or prostate function or clinical response to dutasteride...
  16. ncbi request reprint Free prostate-specific antigen in serum is becoming more complex
    Stephen D Mikolajczyk
    Hybritech Incorporated, San Diego, California 92121, USA
    Urology 59:797-802. 2002
  17. doi request reprint PCA3: a molecular urine assay for predicting prostate biopsy outcome
    Ina L Deras
    Gen Probe, Inc, San Diego, California 92121, USA
    J Urol 179:1587-92. 2008
    ..We further characterized PCA3 performance in different groups of men and determined whether the PCA3 score could synergize with other clinical information to predict biopsy outcome...
  18. ncbi request reprint Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism
    Robert W Veltri
    Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 60:617-22. 2002
    ..Saw palmetto herbal blend (SPHB) causes contraction of prostate epithelial cells and suppression of tissue dihydrotestosterone levels in men with symptomatic benign prostatic hyperplasia, but a fundamental mechanism remains unknown...
  19. ncbi request reprint Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease
    Harry J Linton
    Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc, 7330 Carroll Road, San Diego, CA 92121, USA
    Clin Chem 49:253-9. 2003
    ..We developed an immunoassay to determine the concentration of BPSA in the serum of men with BPH...
  20. ncbi request reprint Treatment of men with minimally symptomatic benign prostatic hyperplasia--PRO: the argument in favor
    Leonard S Marks
    Urology 62:781-3. 2003
  21. ncbi request reprint Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer
    Robert W Veltri
    Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 68:898-904. 2006
    ..To differentiate the benign and/or malignant epithelial cells in prostate cancer (PCa) glands of native Japanese (NJ) and Japanese-American (JA) men using biomarkers...
  22. ncbi request reprint Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    Urology 63:709-15. 2004
    ..To assess the long-term safety and efficacy of dutasteride, a dual type 1 and type 2 5-alpha-reductase inhibitor, in the treatment of symptomatic benign prostatic hyperplasia and associated lower urinary tract symptoms...
  23. ncbi request reprint Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue
    Leonard S Marks
    Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
    Urology 64:765-71. 2004
    ..To investigate the relationship between diet and prostate cancer (CaP) among native Japanese (NJ) and second-generation or third-generation Japanese-American (J-A) men--focusing on the effects of animal fat and soy on prostatic tissues...
  24. ncbi request reprint APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer
    Jack Groskopf
    Gen Probe Incorporated, San Diego, CA 92121, USA
    Clin Chem 52:1089-95. 2006
    ..Prostate cancer gene 3 (PCA3) encodes a prostate-specific mRNA that has shown promise as a prostate cancer diagnostic tool. This report describes the characterization of a prototype quantitative PCA3-based test for whole urine...
  25. ncbi request reprint First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia
    Leonard S Marks
    Urological Sciences Research Foundation and Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, California 90232, USA
    Urology 62:888-93. 2003
    ..Alfuzosin OD is an extended-release formulation of a uroselective, alpha1-adrenoreceptor-blocking agent (alpha-blocker) used in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia...
  26. doi request reprint Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting
    MICHAEL P O'LEARY
    Harvard Medical School, Brigham and Women s Hospital, Boston, MA 02115, USA
    BJU Int 101:1531-5. 2008
    ....
  27. ncbi request reprint PC-SPES: herbal formulation for prostate cancer
    Leonard S Marks
    Urological Sciences Research Foundation, Culver City, California 90232, USA
    Urology 60:369-75; discussion 376-7. 2002
    ..PC-SPES is of great interest in men with androgen-independent CaP, an area in which future research should be primarily directed...
  28. ncbi request reprint Cathepsin B expression in prostate cancer of native Japanese and Japanese-American patients: an immunohistochemical study
    Akhouri A Sinha
    Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Anticancer Res 28:2271-7. 2008
    ....
  29. ncbi request reprint Effects of untreated syphilis in the negro male, 1932 to 1972: a closure comes to the Tuskegee study, 2004
    Shamim M Baker
    Urology 65:1259-62. 2005